Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Boehringer Ingelheim 1-800-243-0127
clintriage.rdg@boehringer-ingelheim.com


Additional US locations available on demand. Please contact for options. 1-800-243-0127


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
Back

Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

Recruiting

Open to: ALL

Age: 18.0 - N/A

London London Sutton

Medical Conditions

Neoplasm Metastasis

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The study has 2 parts. The first part is open to adults with different types of advanced cancer (solid tumours with changes in the HER2 gene) for whom previous treatment was not successful.

The second part is open to people with non-small cell lung cancer with a specific mutation in the HER2 gene.

The purpose of the first study part is to find the highest dose of a medicine called zongertinib the participants can tolerate. Once this dose is found, it will be used in the second study part to test whether zongertinib can make tumours shrink.

In this study, zongertinib is given to people for the first time. Participants take zongertinib as tablets once a day or twice a day.

The participants are in the study for as long as they benefit from and can tolerate treatment.

Study doctors regularly check the participants' health and monitor the tumours. The doctors also take note of any unwanted effects that could have been caused by zongertinib.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Jul 2021 Dec 2026

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : zongertinib

Intervention Arm Group : Phase Ia - Dose escalation part;Phase Ib - Dose expansion part: Cohort 1;Phase Ib - Dose expansion part: Cohort 2;Phase Ib - Dose expansion part: Cohort 3;Phase Ib - Dose expansion part: Cohort 4;Phase Ib - Dose expansion part: Cohort 5;Phase Ib - Dose expansion part: Cohort 6;Phase Ib - Dose expansion part: Cohort 7;Phase Ib - Dose expansion part: Cohort 8;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Hammersmith Hospital
    London
    W12 0HS
  • The Royal Marsden Hospital, Chelsea
    London
    SW3 6JJ
  • The Royal Marsden Hospital, Sutton
    Sutton
    SM2 5PT

Boehringer Ingelheim 1-800-243-0127
clintriage.rdg@boehringer-ingelheim.com


Additional US locations available on demand. Please contact for options. 1-800-243-0127



The study is sponsored by Boehringer Ingelheim



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT04886804
Last updated 25 June 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top